EU Pharmaceutical Legislation Reform

The reform package has two instruments. COM/2023/193 is a proposed Regulation laying down EU procedures for authorisation and supervision of medicinal products and governing the EMA. COM/2023/192 is a proposed Directive establishing a Union code relating to medicinal products. Together they replace Directive 2001/83/EC, Regulation (EC) 726/2004, the orphan and paediatric regulations, and large parts of the EMA's founding architecture.

As of mid-2026 the reform is in trilogue negotiations between Parliament, Council and Commission. The original Commission proposal, the Parliament first-reading position (April 2024), and the Council general approach will be reconciled. Adoption is expected 2026 with phased entry into application 2027–2028. Final text may diverge from the proposal — the description below uses the headline architecture that has remained stable across negotiations.

The current 8+2(+1) structure (8 years data protection, 2 years market protection, +1 for new therapeutic indication) is restructured into a modular scheme. The Commission proposal:

• Baseline regulatory data protection of 6 years (down from 8).
• +2 years if the medicine is launched in all EU Member States within 2 years of authorisation.
• +6 months for addressing an unmet medical need.
• +6 months for conducting comparative clinical trials.
• +1 year for a new therapeutic indication of significant clinical benefit.
• Total ceiling typically 8–9 years; up to 11 in narrow cases.

The reform introduces a Transferable Exclusivity Voucher (TEV) — a tradeable extension of regulatory data protection (typically 12 months) awarded to developers of novel priority antimicrobials. The voucher can be applied to another medicine in the holder's portfolio or sold to a third party. The model is controversial — Member States are split on whether vouchers are cost-effective AMR policy — and the final scope (number of vouchers per year, eligibility, value) is a live trilogue item.

• Marketing Authorisation Holders must notify shortages and discontinuations earlier (typically ≥6 months in advance for foreseeable supply issues, ≥12 months for discontinuations of critical medicines).
• Shortage prevention plans required for medicines on the Union list of critical medicines.
• Strengthened EMA role in managing shortages through the SPOC network and the Medicines Shortages Steering Group (MSSG, established under Regulation (EU) 2022/123).
• Provisions for emergency manufacturing capacity and stockpiling for crisis-relevant medicines.
• Penalties for non-compliance with shortage-notification obligations.

The reform consolidates EMA's committee architecture. Notably the CHMP and CAT (Committee for Advanced Therapies) are merged into a single Committee for Medicinal Products for Human Use with expert working parties for ATMPs, oncology, paediatrics and similar. PRAC and the COMP/PDCO architecture is retained but better integrated. The aim is faster, more coherent assessment with less duplication.

A defined Unmet Medical Need (UMN) status — and a stricter High Unmet Medical Need (HUMN) — qualifies medicines for additional regulatory data protection and for early regulatory dialogue. Compassionate use frameworks are harmonised. The conditional marketing authorisation tool is retained and expanded; the accelerated assessment timeline is shortened from 150 to 120 days for eligible products.

• Environmental risk assessment (ERA) becomes more rigorous; insufficient ERA can be grounds for refusing or amending an MA.
• Antimicrobial-stewardship conditions can be attached to authorisations.
• One Health principles (human, animal, environmental health linkage) appear in the assessment framework, particularly for antibiotics, hormones and APIs of environmental concern.

The Paediatric Regulation and Orphan Regulation are absorbed into the reform package. PIPs (Paediatric Investigation Plans) become more flexible — earlier dialogue, mechanism-of-action triggers, more permissive deferral and waiver criteria. Orphan market exclusivity is restructured into a modular scheme similar to the RDP modular approach, with high-unmet-medical-need orphans retaining the strongest protection.

1. Track trilogue outputs monthly — the final text on RDP, AMR vouchers and orphan exclusivity will materially affect portfolio valuation.
2. Model the launch-in-all-Member-States RDP incentive against your pipeline — does pursuing the +2 years change launch strategy?
3. Operationalise shortage-notification timelines. The ≥6-month / ≥12-month advance notification windows demand earlier S&OP signals than most companies currently produce.
4. If you market antimicrobials, evaluate TEV eligibility for current and pipeline assets.
5. Strengthen ERA processes — environmental risk is moving from condition-of-approval to potential refusal ground.
6. For ATMPs and paediatrics, prepare for revised PIP and assessment processes.